Spyre Therapeutics (NASDAQ: SYRE ) is engaging in the clinical development of multiple antibodies with potential in inflammatory diseases. These antibodies have the potential to be best-in-class, but intelligent trial design and development decisions may meanScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice. ...